Efficient carrier based on nuclear localization signal and C / D box stem-loop structure and delivery method thereof

By adding nuclear localization signals and C/D box stem loop structure on Cas9 mRNA, combined with L7Ae protein, and using VLP vector to deliver to target cells, the problem of low editing efficiency of CRISPR-Cas9 in the prior art was solved, achieving more efficient gene editing effect.

CN118995824APending Publication Date: 2024-11-22SHANGHAI BAILIAN BIOMEDICAL TECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411424263.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-12
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the RNA delivery technology, the specific binding efficiency of MS2C and stem loops is low, resulting in low editing efficiency of CRISPR-Cas9, and only a small amount of Cas9 mRNA enters the cell nucleus after being expressed into protein in the cytoplasm, resulting in gene editing. Inefficient.

Method used

Using a high-efficiency vector based on nuclear localization signal and C/D box stem loop structure, the Cas9 mRNA carrying nuclear localization signal NLS in the head and tail is combined with the L7Ae protein, and the VLP vector is used to deliver it to the target cells, thereby improving the entry efficiency of Cas9 protein. , thereby enhancing the gene editing efficiency of CRISPR-Cas9.

Benefits of technology

It significantly improves the packaging rate and nuclear entry rate of Cas9 mRNA, enhances the gene editing efficiency of CRISPR-Cas9, reduces the "off-target" effect, and improves the accuracy and efficiency of gene editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995824A_ABST
    Figure CN118995824A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of virus-like particles, and particularly relates to an efficient vector based on a nuclear localization signal and a C / D box stem-loop structure and a delivery method of the efficient vector. According to the method, the delivery efficiency and gene editing efficiency of Cas9 in the VLP vector are improved by utilizing a protein-stem-loop structure combination L7Ae-C / Dbox. The efficient vector based on the nuclear localization signal and the C / Dbox stem-loop structure can be developed into reagents or drugs for disease prevention, diagnosis or treatment, especially gene editing reagents or drugs, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of virus-like particles, and specifically relates to a high-efficiency VLP vector based on a nuclear localization signal and a C / D box stem-loop structure and a delivery method thereof, in particular to a method for delivering mRNA. Background Art

[0002] VLP (virus like particle) technology is derived from the lentiviral system, which can use the high affinity of the virus to achieve effective intracellular delivery. The delivery targets can be nucleic acids, proteins, or ribonucleoproteins (RNPs), etc. Most traditional lentiviral vectors deliver target DNA or RNA in the form of DNA integration, which is continuously translated into Cas9 protein, resulting in a high probability of "off-target" effects (gene shearing that is unrelated to the original designed gene shearing effect). In actual applications, VLP can deliver Cas9 to the human body in the form of mRNA instantly to achieve the purpose of treatment while greatly reducing off-target effects.

[0003] The specific binding principle of MS2C and stem loop is adopted in the existing lentiviral vector delivery RNA technology, such as CN108504689A lentiviral vector and its method for delivering exogenous RNA, which utilizes the principle of mutual binding between RNA binding protein and the RNA sequence recognized by it, integrates RNA binding protein into the backbone of lentiviral GagPol long-chain protein, and connects the recognized RNA sequence to the exogenous target RNA, so that the target RNA is packaged into lentiviral particles during the assembly process of lentiviral particles. After the MS2 phage capsid protein (MS2C) and the lentiviral GagPol protein are fused, they are expressed in the core of VLP. Using the principle that the stem-loop structure (stem loop) can specifically recognize and bind to the MS2C protein, after the Cas9 protein mRNA and stemloop are fused, the stem loop is specifically bound to the MS2C in the VLP core, and the Cas9 protein mRNA is introduced into the VLP core; at the same time, the gRNA for a specific gene is cloned into the lentiviral shuttle plasmid, and finally a VLP with a lentiviral structure similar to Cas9 mRNA and gRNA is assembled. VLP delivers Cas9 mRNA and gRNA to the cytoplasm of target cells, and by translating cas9 protein, exerts the gene editing effect of the CRISPR-Cas9 system in the target cells. However, the specific binding efficiency of MS2C and stem loop is low, resulting in low CRISPR-Cas9 editing efficiency. Cas9 mRNA is expressed as protein in the cytoplasm, and only a small amount enters the cell nucleus to exert the CRISPR-Cas9 editing effect, resulting in low editing efficiency.

[0004] Therefore, it is necessary to develop new virus-like particle delivery technologies, improve the virus-like particle encapsulation rate of exogenous target DNA, RNA or protein, and improve the nuclear entry rate of exogenous target DNA, RNA or protein, improve the action efficiency of exogenous target DNA, RNA or protein, and continuously improve the virus-like particle delivery technology. Summary of the invention

[0005] The present invention utilizes the high binding property of the C / Dbox stem-loop structure and the L7Ae protein to encapsulate the Cas9 mRNA (NLS-Cas9-NLS) carrying the nuclear localization signal NLS at both ends into the VLP vector core, and delivers the Cas9 mRNA to the target cell instantaneously via the VLP vector. The efficiently expressed Cas9 protein increases the efficiency of Cas9 protein entering the nucleus under the action of NLS, and ultimately improves the gene editing efficiency of Cas9. The efficient vector based on the nuclear localization signal and the C / Dbox stem-loop structure can be a VLP (virus-like particle) vector, exosome, lentivirus, and AAV (adeno-associated virus) vector.

[0006] The present invention provides a nucleic acid sequence encoding and expressing Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) carrying a nuclear localization signal NLS at both ends and connected to a C / Dbox stem-loop structure, as shown in SEQ ID NO: 1.

[0007] A Cas9 mRNA expression vector, carrying a nucleic acid sequence encoding and expressing Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) carrying a nuclear localization signal NLS at both ends and connected to a C / Dbox stem-loop structure, as shown in SEQ ID NO: 1, specifically pCMV.

[0008] A Cas9 mRNA is encoded and expressed by the nucleic acid sequence shown in SEQ ID NO: 1. Both ends of the Cas9 mRNA carry a nuclear localization signal NLS and are connected to a C / Dbox stem-loop structure. There are 6 C / Dbox stem-loop structures.

[0009] The present invention provides a nucleic acid sequence encoding and expressing L7Ae protein, as shown in SEQ ID NO: 2; the L7Ae protein is combined with a C / Dbox stem-loop structure connected to mRNA carrying a nuclear localization signal NLS at the head and tail.

[0010] An L7Ae protein expression vector carries a nucleic acid sequence encoding the expression of the L7Ae protein, the nucleic acid sequence of which is shown in SEQ ID NO: 2, specifically pMS2M. An L7Ae protein expression vector also carries a nucleic acid coding sequence of the GagPol protein.

[0011] The present invention provides a gRNA sequence for guiding Cas9 protein, which is AAVS1 gRNA, as shown in SEQ ID NO:3.

[0012] A gRNA expression vector carrying the AAVS1 gRNA nucleic acid sequence shown in SEQ ID NO: 3, specifically pLV.

[0013] The Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) provided by the present invention, which carries a nuclear localization signal NLS at both ends and is connected to a C / Dbox stem-loop structure, can be used to prepare a vector for clinical use, wherein the L7Ae protein bound to the C / Dbox stem-loop structure is fused to the vector core, and the vector includes a VLP vector, an exosome vector, a lentiviral vector, and an AAV vector.

[0014] The nucleic acid coding sequence of the Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) carrying the nuclear localization signal NLS at the beginning and the end and connected with the C / Dbox stem-loop structure is shown in SEQ ID NO: 1.

[0015] The nucleic acid coding sequence of the L7Ae protein is shown in SEQ ID NO:2.

[0016] The present invention provides an efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure, comprising a vector particle, a Cas9 mRNA located in the vector particle and carrying a nuclear localization signal NLS at the head and tail and connected to a C / Dbox stem-loop structure, and a gRNA located in the vector particle. The vector particle comprises a vector particle shell composed of a structural protein and a GagPol protein fused to an L7Ae protein located in the vector particle shell. The C / Dbox stem-loop structure and the L7Ae protein are combined with each other to encapsulate the Cas9 mRNA into the vector particle.

[0017] The nucleic acid coding sequence of the Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) carrying the nuclear localization signal NLS at the beginning and the end and connected with the C / Dbox stem-loop structure is shown in SEQ ID NO: 1.

[0018] The nucleic acid coding sequence of the L7Ae protein is shown in SEQ ID NO:2.

[0019] The gRNA is AAVS1 gRNA, and its sequence is shown in SEQ ID NO:3.

[0020] The high-efficiency vectors based on nuclear localization signals and C / Dbox stem-loop structures provided by the present invention include VLP vectors, exosome vectors, lentiviral vectors, and AAV vectors.

[0021] The present invention is based on the efficient carrier of nuclear localization signal and C / Dbox stem-loop structure and can be used for delivery applications of animals, human body and in vitro cells, and delivers exogenous nucleic acids, exogenous proteins, exogenous polypeptides and other exogenous substances. For example, the efficient carrier based on nuclear localization signal and C / Dbox stem-loop structure delivers Cas9 and gRNA, and the gene is effectively edited by the synergistic effect of Cas9 and gRNA (i.e., RNA-guided CRISPR-Cas nuclease editing technology), and the physiological function of the person is purposefully adjusted for the prevention, treatment and diagnosis of human diseases. Specifically, such as modifying the specific target of the genome of the organism through gene editing, correcting gene defects or exerting therapeutic effects, and achieving the purpose of treating the disease. Gene editing tools enter cells for gene editing, forming gene editing therapy, and providing new directions for the diagnosis and treatment of diseases.

[0022] The high-efficiency vector based on the nuclear localization signal and C / Dbox stem-loop structure provided by the present invention can be used to develop reagents or drugs for disease prevention, diagnosis, or treatment, especially gene editing reagents or drugs, to perform gene editing on target tissues or cells, exert intervention effects, regulate physiological functions, and achieve the purpose of preventing, diagnosing, and treating diseases.

[0023] A reagent or drug for disease prevention, diagnosis, or treatment, the invention provides an efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure. The efficient vector based on the nuclear localization signal and the C / Dbox stem-loop structure delivers the encapsulated Cas9 and gRNA into the target tissue or cell, intervenes in the regulation of physiological functions, and especially intervenes in the gene editing process to generate a gene editing reagent or drug, thereby playing a role in preventing, diagnosing, and treating diseases.

[0024] In order to obtain a highly expressed, stable and efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure, the present invention provides an assembly system for an efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure, including an expression vector of a structural protein constituting the outer shell of a vector particle, an expression vector of a GagPol protein fused with an L7Ae protein, an expression vector of a Cas9mRNA fused with a nuclear localization signal NLS at the head and tail and connected with a C / Dbox stem-loop structure, and an expression vector of a gRNA.

[0025] The expression vectors of the structural proteins constituting the outer shell of the vector particles include PMD.2G, pRSV-REV and pMDlg / pRRE-D64V.

[0026] The expression vector of the GagPol protein fused with the L7Ae protein is pMS2M, and the coding sequence of L7Ae is shown in SEQ ID NO:2.

[0027] The expression vector fused with the Cas9 mRNA carrying the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure is pCMV, and the nucleic acid coding sequence of the Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) carrying the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure is shown in SEQ ID NO: 1.

[0028] The expression vector of the gRNA is pLV, and the gRNA is AAVS1 gRNA, and its sequence is shown in SEQ ID NO:3.

[0029] In order to efficiently deliver a high-efficiency vector based on a nuclear localization signal and a C / Dbox stem-loop structure to a target tissue or cell and exert a high-efficiency physiological function regulating activity in the target cell, the present invention provides a delivery method of a high-efficiency vector based on a nuclear localization signal and a C / Dbox stem-loop structure, the steps comprising: co-transfecting an assembly system of a high-efficiency vector based on a nuclear localization signal and a C / D box stem-loop structure into a host cell, collecting a supernatant after culturing, and infecting the target tissue or cell with the supernatant.

[0030] The assembly system of the efficient vector based on the nuclear localization signal and the C / Dbox stem-loop structure includes an expression vector of the structural protein constituting the outer shell of the vector particle, an expression vector of the GagPol protein fused with the L7Ae protein, an expression vector of the Cas9 mRNA fused with the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure, and an expression vector of the gRNA.

[0031] The expression vectors of the structural proteins constituting the outer shell of the vector particles include PMD.2G, pRSV-REV and pMDlg / pRRE-D64V.

[0032] The expression vector of the GagPol protein fused with the L7Ae protein is pMS2M-PH, and the coding sequence of L7Ae is shown in SEQ ID NO:2.

[0033] The expression vector fused with the Cas9 mRNA carrying the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure is pCMV, and the nucleic acid coding sequence of the Cas9 mRNA (NLS-Cas9-NLS+6×CD box2) carrying the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure is shown in SEQ ID NO: 1.

[0034] The expression vector of the gRNA is pLV, and the gRNA is AAVS1 gRNA, and its sequence is shown in SEQ ID NO:3.

[0035] The present invention also provides a carrier particle, comprising a carrier particle shell composed of structural proteins and a GagPol protein fused with L7Ae protein located in the carrier particle shell.

[0036] The nucleic acid coding sequence of the L7Ae protein is shown in SEQ ID NO:2.

[0037] A vector particle assembly system comprises an expression vector of a structural protein constituting a vector particle shell and an expression vector of a GagPol protein fused with an L7Ae protein.

[0038] The expression vectors of the structural proteins constituting the outer shell of the vector particles include PMD.2G, pRSV-REV and pMDlg / pRRE-D64V.

[0039] The expression vector of the GagPol protein fused with the L7Ae protein is pMS2M-PH, and the coding sequence of L7Ae is shown in SEQ ID NO:2.

[0040] The embodiment of the present invention verifies the above technical scheme of the present invention. The VLP delivery technology used in the embodiment of the present invention uses lentivirus as the vector skeleton, and the L7Ae protein and the lentivirus GagPol protein are fused and expressed in the core of the VLP. Utilizing the principle that the stem-loop structure C / D box can specifically recognize and bind to the L7Ae protein, the Cas9 protein mRNA (NLS-Cas9-NLS) with NLS and the stem-loop structure C / D box are fused, and the Cas9 protein mRNA is introduced into the VLP core through the specific binding of the C / D box to the L7Ae in the VLP core; at the same time, the gRNA for a specific gene is cloned into the lentivirus shuttle plasmid, and finally a VLP with a lentivirus-like structure carrying the Cas9 protein mRNA and gRNA is assembled. VLP delivers the Cas9 protein mRNA and gRNA to the cytoplasm of the target cell, and exerts the "instantaneous" gene editing effect of the CRISPR-Cas9 system in the target cell by translating the Cas9 protein mRNA in a short time.

[0041] Nuclear Localization Signal (NLS) is a specific amino acid sequence in protein molecules that can guide the transfer of proteins from the cytoplasm to the nucleus. NLS usually contains positively charged amino acid residues, such as lysine and arginine, which interact with nuclear importin to promote the nuclear localization of proteins. Adding NLS sequences to both sides of the Cas9 gene can increase the nuclear entry of Cas9 protein and enhance the gene editing effect.

[0042] L7Ae protein is a highly conserved protein belonging to the L7Ae protein family. It can bind to the special stem-loop structure C / D box in the ribosome. The present invention significantly improves the delivery efficiency of the VLP vector by replacing the stem-loop combination MS2C-Stem loop with L7Ae-C / D box and adding NLS, and develops a more efficient VLP delivery vector for transient expression.

[0043] In view of the defects that 1) the specific binding efficiency of MS2C and stem loop in the existing lentiviral vector RNA delivery technology is low, resulting in low CRISPR-Cas9 editing efficiency; 2) Cas9 mRNA is expressed as protein in the cytoplasm, and only a small amount enters the cell nucleus to exert the CRISPR-Cas9 editing effect, resulting in low editing efficiency, the present invention specifically proposes a technical solution to improve the technical defects, and obtains 1) replacing the MS2C-stem loop combination with the protein-stem-loop structure combination L7Ae-C / D box to improve the mRNA delivery efficiency and CRISPR-Cas9 editing efficiency of the VLP vector; 2) adding NLS at both ends of the Cas9 gene can increase the significant technical effects of increasing the nuclear entry of Cas9 protein and the gene editing efficiency of VLP. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 This is a diagram to test the effect of removing residual plasmids.

[0045] Figure 2 This is the fluorescence observation image at 96 hours of infection.

[0046] Figure 3 The flow cytometry results of the VLP-2NLS-L7Ae-C / D box group are shown in Figure 1. From left to right, they are the main cell population sorting image, the de-adhesion cell image, and the single cell image.

[0047] Figure 4 The flow cytometry results of the VLP-MS2C-Stem loop group are shown in Figure 1. From left to right, they are the main cell population sorting image, the de-adhesion cell image, and the single cell image.

[0048] Figure 5 The flow cytometry results of the NC group are shown in Figure 1. From left to right, they are the main cell population sorting diagram, the de-adhesion cell diagram, and the single cell diagram.

[0049] Figure 6 Editing effect diagram of AAVS1 for T7E1 detection.

[0050] Figure 7 This is the AAVS1 gene editing efficiency diagram of the VLP-2NLS-L7Ae-C / D box group.

[0051] Figure 8This is the AAVS1 gene editing efficiency diagram of the VLP-MS2C-Stem loop group.

[0052] Fig. 9 This is a significant analysis of the differences in AAVS1 gene editing efficiency between the VLP-2NLS-L7Ae-C / D box and VLP-MS2C-Stem loop groups.

[0053] Fig.10 The expression of Cas9 protein in cells infected with VLP-2NLS-L7Ae-C / D box and VLP-MS2C-Stem loop groups was detected at different time periods.

[0054] Fig.11 Schematic diagram of the construction of pCMV-2NLS-Cas9-6×C / D box plasmid.

[0055] Fig.12 Schematic diagram of the construction of pLV-egfp-U3-sp.gRNA plasmid.

[0056] Fig.13 Schematic diagram of the construction of PMDlg / pRRE-D64V plasmid.

[0057] Fig.14 Schematic diagram of the construction of pMS2M-PH-Gag-Pol-D64V plasmid. DETAILED DESCRIPTION

[0058] The technical solution of the present invention is described below in conjunction with specific embodiments.

[0059] 1. Plasmid construction

[0060] 1.pCMV-2NLS-Cas9-6×C / D box plasmid

[0061] The sequence between GFP and poly(A) in the pCMV-GFP (manufacturer: Miaoling Plasmid Platform, catalog number: P20780) plasmid was replaced with the NLS-cas9-NLS+6×C / D box sequence. This was done in three steps: first inserting the Cas9 sequence, then inserting the 6×C / D box sequence, and finally adding NLS at both ends of the Cas9 gene to obtain the pCMV-2NLS-Cas9-6×C / D box plasmid.

[0062] NLS-Cas9-NLS+6×CD box2 gene sequence (SEQ ID NO: 1):

[0063]

[0064] 2.pLV-egfp-U3-sp.gRNA plasmid

[0065] Insert the EGFP sequence into the pLV lentiviral shuttle plasmid. Insert the U6 promoter sequence into the U3 region of 3'LTR to obtain the pLV-egfp plasmid. Then anneal the AAVS1 gRNA-F (sequence: CACCGGGGCCACTAGGGACAGGAT, SEQ ID NO:4) and AAVS1 gRNA-R (sequence: AAACATCCTGTCCCTAGTGGCCCC, SEQ ID NO:5) to obtain a double-stranded AAVS1 gRNA. Then, the pLV-egfp plasmid was digested with Aar I enzyme (manufacturer: ThermoFisher Scientific, catalog number: ER1581), and the AAVS1 gRNA double-stranded was cloned into the pLV-egfp plasmid to obtain the pLV-egfp-U3-AAVS1-sp.gRNA plasmid. The AAVS1 gRNA sequence is (SEQ ID NO:3): GGGGCCACTAGGGACAGGAT.

[0066] 3.PMDlg / pRRE-D64V plasmid transformation

[0067] The amino acid GAT (D) at position 64 of the Integrase gene in the pol region of the pMDLg-pRRE plasmid was mutated to GTT (V).

[0068] 4.L7Ae-PH-Gag-Pol-D64V plasmid transformation

[0069] The pMS2M-PH-Gag-Pol-D64V plasmid was purchased from Miaoling Plasmid Platform, catalog number: P37491, and the MS2C gene in the plasmid was replaced with the L7Ae gene.

[0070] L7Ae gene sequence (SEQ ID NO: 2):

[0071] atgggaggcggaggcggaggcggaggcatgtacgtgagatttgaggttcctgaggacatgcagaacgaagctctgagtctgctggagaaggttagggagagcggtaaggtaaagaaaggtaccaacgagacgacaaaggctgtggagaggggactggcaaagctcgtttacatcgcagaggatgttgacccg cctgagatcgttgctcatctgcccctcctctgcgaggagaagaatgtgccgtacatttacgttaaaagcaagaacgaccttggaagggctgtgggcattgaggtgccatgcgcttcggcagcgataatcaacgagggagagctgagaaaggagcttggaagccttgtggagaagattaaaggccttcagaag

[0072] 5.PMD.2G and pRSV-REV plasmids are from the third generation lentiviral plasmids.

[0073] II. Transfection and Infection

[0074] 1. Plate cells in a 15 cm cell culture dish, adding 1.6E5 cells / cm to each well. 2 HEK-293T cells, cultured for 24h.

[0075] 2. After 24 hours, replace the cell culture medium in the 15 cm well plate with 1 mL 2% FBSDMEM and incubate at 37°C.

[0076] 3. Transfection was performed in a 15 cm cell culture dish at a ratio of 1 μg DNA (total) to PEI (polyplus) to 2 μL. The transfection dose is as follows:

[0077] Plasmid name Plasmid transfection amount per well (μg) PMD.2G 7.2 pRSV-REV 5.77 pCMV-2NLS-Cas9-6×C / D box 25 pLV-egfp-U3-sp.gRNA 25 L7Ae-PH-Gag-Pol-D64V 12.5 pMDlg / pRRE-D64V 12.5

[0078] 10% FBSDMEM was replaced 6 hours after transfection, and 30 mL of supernatant was collected at 72 hours and recorded as the VLP-2NLS-L7Ae-C / D box experimental group.

[0079] 4. Removal of residual plasmids:

[0080] Add nuclease to the collected supernatant. After 1 hour of reaction, nucleic acid test for the removal of residual plasmid. The test results are as follows: Figure 1 It shows that the residual plasmid is completely removed. Figure 1The construction of VLP-MS2C-Stem loop adopts the construction method described in Example CN108504689A.

[0081] 5. VLP Concentration:

[0082] The supernatant after the removal of nucleic acid was centrifuged at 4°C and 25,000 rpm for 2 h. After the supernatant was discarded, PBS with a volume of 1 / 50 of the original supernatant was added, and the supernatant was dissolved and resuspended overnight. The volume after concentration was 600 μL.

[0083] 6. Transduction titer detection (flow cytometry):

[0084] The plate was spread about 12 hours in advance, and the cell amount in each well was 1E5. Infection experiments were performed, and three groups were set up. One group of cells was added with DMEM as the NC group, one group of cells was added with VLP based on the MS2C-Stemloop structure reported in CN108504689A as the control, and the last group of cells was added with VLP based on the 2NLS-L7Ae-C / D box structure. Cells were collected 96 hours after infection, and the proportion of green fluorescence positive cells was detected by flow cytometry to calculate the transduction titer.

[0085] Fluorescence observation results: Figure 2 As shown, the number of EGFP fluorescence positive cells in the VLP-2NLS-C / D box (same as VLP-2NLS-L7Ae-C / D box) group was 29.44%, and the number of EGFP fluorescence positive cells in the VLP-MS2 (same as VLP-MS2C-Stem loop) group was 70.60%.

[0086] Flow cytometry results: VLP was diluted 1000 times, and 100 μL was taken to infect 1E5 293T cells. Flow cytometry showed that the ratio of green fluorescence positive cells was Figure 3-Figure 5 The transduction titer of the VLP-2NLS-L7Ae-C / D box group was calculated to be 2.944E7 TU / mL, and the transduction titer of the VLP-MS2C-Stem loop group was 7.06E8 TU / mL.

[0087] 7.AAVS1 editing efficiency detection

[0088] The transfected and concentrated VLP supernatant was used to infect 293T cells. The cells were collected 5 days after infection. T7E1 was used to detect whether the AAVS1 gene was edited, and the grayscale was scanned to calculate the editing efficiency. The detection primers are as follows:

[0089] Primer name Primer sequences T7E1-AAVS1 F SEQ ID NO:6 CCAGACAGCCGCGTCAGA T7E1-AAVS1 R SEQ ID NO:7 CCTGCCGCCTCCTTCAGG

[0090] The results of the T7E1 editing efficiency test are as follows Figure 6The results showed that both the VLP-2NLS-L7Ae-C / D box group and the VLP-MS2C-Stem loop group could cut the target gene into two segments. Under the same VLP infection dose, the editing efficiency of the VLP-2NLS-L7Ae-C / D box group was significantly higher than that of the VLP-MS2C-Stem loop group.

[0091] The transfected and concentrated VLP supernatant was used to infect 293T cells. After 5 days of infection, the cells were collected and the cell DNA was extracted. After amplification with T7E1-AAVS1 F primers, Sanger sequencing was performed, and then the AAVS1 gene editing efficiency was detected by TIDE. The TIDE detection results are shown in Figure 2. Figure 7-9 As shown, under the conditions of the same VLP infection dose, the editing efficiency of the VLP-2NLS-L7Ae-C / D box group was 58.1%, and the editing efficiency of the VLP-MS2C-Stem loop group was 17.5%. The editing efficiency of the VLP-2NLS-L7Ae-C / D box group was significantly higher than that of the VLP-MS2C-Stem loop group.

[0092] 8. Cas9 WB detection

[0093] 12 hours before infection, cells were plated in 6-well cell culture plates with 1E6 cells per well. After cells adhered to the wall, VLP-2NLS-L7Ae-C / D box group and VLP-MS2C-Stem loop group VLPs were added to the cells. Cells were collected 24h, 48h and 72h after infection for WB detection of Cas9 expression.

[0094] After testing, such as Fig.10 , the expression of Cas9 protein could be detected in both the VLP-2NLS-L7Ae-C / D box group and the VLP-MS2C-Stem loop group at 24h and 48h after infection, but no expression of Cas9 protein could be detected at 72h, indicating that Cas9 protein would be degraded at 72h, greatly reducing the risk of "off-target effect" of traditional lentiviral delivery.

[0095] It should be pointed out that the above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology of this project to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. An efficient vector based on nuclear localization signal and C / Dbox stem-loop structure, characterized in that: It includes a vector particle, a Cas9 mRNA located in the vector particle and carrying a nuclear localization signal NLS at the head and tail and connected to a C / Dbox stem-loop structure, and a gRNA located in the vector particle. The vector particle includes a vector particle shell composed of structural proteins and a GagPol protein fused with an L7Ae protein located in the vector particle shell. The C / Dbox stem-loop structure and the L7Ae protein are combined with each other to encapsulate the Cas9 mRNA into the vector particle. The nucleic acid coding sequence of the Cas9 mRNA carrying the nuclear localization signal NLS at the head and tail and connected to the C / Dbox stem-loop structure is shown in SEQ ID NO: 1; The nucleic acid coding sequence of the L7Ae protein is shown in SEQ ID NO: 2; The gRNA is AAVS1 gRNA, and its sequence is shown in SEQ ID NO:

3.

2. An efficient vector assembly system based on nuclear localization signal and C / Dbox stem-loop structure, characterized in that: Including expression vectors of structural proteins constituting the outer shell of vector particles, expression vectors of GagPol protein fused with L7Ae protein, expression vectors of Cas9 mRNA fused with nuclear localization signal NLS at the head and tail and connected with C / Dbox stem-loop structure, and expression vectors of gRNA; The expression vectors of the structural proteins constituting the outer shell of the vector particles include PMD.2G, pRSV-REV and pMDlg / pRRE-D64V; The expression vector of the GagPol protein fused with the L7Ae protein is pMS2M, and the coding sequence of L7Ae is shown in SEQ ID NO: 2; The expression vector fused with the Cas9 mRNA carrying the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure is pCMV, and the nucleic acid coding sequence of the Cas9 mRNA carrying the nuclear localization signal NLS at the head and tail and connected with the C / Dbox stem-loop structure is shown in SEQ ID NO: 1; The expression vector of the gRNA is pLV, and the gRNA is AAVS1 gRNA, and its sequence is shown in SEQ ID NO:

3.

3. The assembly system of a high-efficiency vector based on a nuclear localization signal and a C / Dbox stem-loop structure as described in claim 1 or a high-efficiency vector based on a nuclear localization signal and a C / Dbox stem-loop structure as described in claim 2 is used for delivery applications in animals, humans or in vitro cells or for preparing reagents or drugs for disease prevention, diagnosis, or treatment.

4. A reagent or drug for disease prevention, diagnosis, or treatment, characterized in that: An assembly system comprising an efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure as described in claim 1 or an efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure as described in claim 2.

5. A method for delivering an efficient vector based on a nuclear localization signal and a C / Dbox stem-loop structure, characterized in that the steps include: The assembly system of a high-efficiency vector based on a nuclear localization signal and a C / D box stem-loop structure as described in claim 2 is co-transfected into a host cell, and the supernatant is collected after culturing, and the supernatant infects the target tissue or cell.

6. A nucleic acid sequence encoding and expressing Cas9 mRNA carrying a nuclear localization signal NLS at both ends and connected to a C / Dbox stem-loop structure, characterized in that: As shown in SEQ ID NO:

1.

7. Cas9 mRNA carrying a nuclear localization signal NLS at both ends and connected to a C / Dbox stem-loop structure is used to prepare a vector for clinical use, wherein the L7Ae protein bound to the C / Dbox stem-loop structure is fused to the core of the vector, and the vector includes a VLP vector, an exosome vector, a lentiviral vector, and an AAV vector; The nucleic acid coding sequence of the Cas9 mRNA carrying the nuclear localization signal NLS at the head and tail and connected to the C / Dbox stem-loop structure is shown in SEQ ID NO: 1; The nucleic acid coding sequence of the L7Ae protein is shown in SEQ ID NO:

2.

8. A nucleic acid sequence encoding and expressing L7Ae protein, characterized in that: As shown in SEQ ID NO: 2, the L7Ae protein binds to a C / Dbox stem-loop structure connected to the mRNA carrying a nuclear localization signal NLS at the head and tail.

9. A gRNA sequence for guiding Cas9 protein, characterized in that: It is AAVS1 gRNA, and the sequence is shown in SEQ ID NO:

3.

10. The present invention also provides a carrier particle, characterized in that: It includes a vector particle shell composed of structural proteins and a GagPol protein fused with an L7Ae protein located in the vector particle shell; The nucleic acid coding sequence of the L7Ae protein is shown in SEQ ID NO:2.

Citation Information

Patent Citations

  • Lentiviral vector and method thereof for delivering external source RNA

    CN108504689A